Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Discontinue Two Humulins - Ultralente and Lente - By Year-End

This article was originally published in The Pink Sheet Daily

Executive Summary

Company says declining commercial demand is the reason for its decision to discontinue production of the longer-acting Humulins as well as Iletin insulins. Lilly sends out "Dear Doctor" letters and will help transition patients to the company's other insulin products through coupons for free samples.

You may also be interested in...



Lilly To Discontinue Select Humulin Offerings (Correction)

Lilly will discontinue only the Ultralente and Lente formulations of Humulin human insulin. The firm will continue to manufacture Humulin R, N, 70/30 and 50/50 formulations. "The Pink Sheet" DAILY had inadvertently suggested that all Humulin formulations were to be discontinued by year-end (1"The Pink Sheet" DAILY, July 6, 2005)

Tarceva Pancreatic Cancer Indication Turned Down In The EU

Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.

Topics

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel